208 related articles for article (PubMed ID: 34586831)
1. Aberrant activation of m6A demethylase FTO renders HIF2α
Zhang C; Chen L; Lou W; Su J; Huang J; Liu A; Xu Y; He H; Gao Y; Xu D; Li Q
Sci Transl Med; 2021 Sep; 13(613):eabf6045. PubMed ID: 34586831
[TBL] [Abstract][Full Text] [Related]
2. Bromodomain-containing protein 9 is a prognostic biomarker associated with immune infiltrates and promotes tumor malignancy through activating notch signaling pathway in negative HIF-2α clear cell renal cell carcinoma.
Lou W; Gao K; Xu C; Li Q
IUBMB Life; 2021 Nov; 73(11):1334-1347. PubMed ID: 34415102
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis.
Zhuang C; Zhuang C; Luo X; Huang X; Yao L; Li J; Li Y; Xiong T; Ye J; Zhang F; Gui Y
J Cell Mol Med; 2019 Mar; 23(3):2163-2173. PubMed ID: 30648791
[TBL] [Abstract][Full Text] [Related]
4. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
[TBL] [Abstract][Full Text] [Related]
5. Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival.
Zhao J; Lu L
Recent Pat Anticancer Drug Discov; 2021; 16(3):363-376. PubMed ID: 33563180
[TBL] [Abstract][Full Text] [Related]
6. The m
Xiao Y; Thakkar KN; Zhao H; Broughton J; Li Y; Seoane JA; Diep AN; Metzner TJ; von Eyben R; Dill DL; Brooks JD; Curtis C; Leppert JT; Ye J; Peehl DM; Giaccia AJ; Sinha S; Rankin EB
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21441-21449. PubMed ID: 32817424
[TBL] [Abstract][Full Text] [Related]
7. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma.
Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H
Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636
[TBL] [Abstract][Full Text] [Related]
8. Erratum for the Research Article "Aberrant activation of m6A demethylase FTO renders HIF2α
Sci Transl Med; 2023 Jun; 15(702):eadj2190. PubMed ID: 37379372
[No Abstract] [Full Text] [Related]
9. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
10. The m
He Y; Chen Y; Li Z; Wu C
J Cancer Res Clin Oncol; 2024 Jan; 150(2):30. PubMed ID: 38270643
[TBL] [Abstract][Full Text] [Related]
11. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
12. The m6A modification-mediated OGDHL exerts a tumor suppressor role in ccRCC by downregulating FASN to inhibit lipid synthesis and ERK signaling.
Shi J; Miao D; Lv Q; Wang K; Wang Q; Liang H; Yang H; Xiong Z; Zhang X
Cell Death Dis; 2023 Aug; 14(8):560. PubMed ID: 37626050
[TBL] [Abstract][Full Text] [Related]
13. FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability.
Xu Y; Zhou J; Li L; Yang W; Zhang Z; Zhang K; Ma K; Xie H; Zhang Z; Cai L; Gong Y; Gong K
Int J Biol Sci; 2022; 18(15):5943-5962. PubMed ID: 36263177
[TBL] [Abstract][Full Text] [Related]
14. USP37 promotes deubiquitination of HIF2α in kidney cancer.
Hong K; Hu L; Liu X; Simon JM; Ptacek TS; Zheng X; Liao C; Baldwin AS; Zhang Q
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):13023-13032. PubMed ID: 32461361
[TBL] [Abstract][Full Text] [Related]
15. HIF2α promotes tumour growth in clear cell renal cell carcinoma by increasing the expression of NUDT1 to reduce oxidative stress.
Shi J; Xiong Z; Wang K; Yuan C; Huang Y; Xiao W; Meng X; Chen Z; Lv Q; Miao D; Liang H; Xu T; Xie K; Yang H; Zhang X
Clin Transl Med; 2021 Nov; 11(11):e592. PubMed ID: 34841698
[TBL] [Abstract][Full Text] [Related]
16. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
[TBL] [Abstract][Full Text] [Related]
17. The role of HIF1α in renal cell carcinoma tumorigenesis.
Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
[TBL] [Abstract][Full Text] [Related]
18. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
[TBL] [Abstract][Full Text] [Related]
19. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
[TBL] [Abstract][Full Text] [Related]
20. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
